Serious hypersensitivity reactions in patients w/ no prior exposure to sulphur hexafluoride microbubbles products; may increase risk of serious reactions in patients w/ prior hypersensitivity reaction to polyethylene glycol; closely supervise patients during & for at least 30 min following administration. Treating anaphylaxis w/ epinephrine in patients on β-blockers. Perform ECG monitoring in high-risk patients w/ unstable cardiopulmonary status as clinically indicated. Patients w/ recent acute coronary syndrome or clinically unstable ischaemic cardiac disease including evolving or ongoing MI, typical angina at rest w/in last 7 days, significant worsening of cardiac symptoms w/in last 7 days, recent coronary artery intervention or other factors suggesting clinical instability, acute cardiac failure, class III/IV cardiac failure or severe rhythm disorders. Patients must have a stable condition when used in conjunction w/ stress echocardiography during the 2 preceding days. Perform ECG & BP monitoring during SonoVue-enhanced echocardiography w/ pharmacological stress (eg, dobutamine). Acute endocarditis, prosthetic valves, acute systemic inflammation &/or sepsis, hyperactive coagulation states &/or recent thromboembolism, end-stage renal or hepatic disease. False -ve cases can occur w/ voiding ultrasonography w/ SonoVue. Contains Na <1 mmol. Avoid use during pregnancy. Not known if sulphur hexafluoride is excreted in human milk; may consider to resume breastfeeding 2-3 hr after administration. Safety & efficacy in patients <18 yr has not been established for IV administration & use in echocardiography & vascular doppler imaging.